Corporate Presentation January 2026 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects ...

Core Insights - Sana Biotechnology, Inc. is set to present updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for type 1 diabetes at the upcoming American Diabetes Association (ADA) Scientific Sessions [1] - The presentation will focus on the first-in-human study of UP421, an allogeneic primary islet cell therapy utilizing Sana's hypoimmune (HIP) technology, which does not require immunosuppression [1] Presentation Details - The presentation titled "Hypoimmune Pancreatic Islet Transplantation in Adult Subjects with Type 1 Diabetes" will take place on June 23, 2025, from 9:00 to 9:20 a.m. CT at the joint ADA/IPITA symposium [2] - The symposium is themed "Outpacing the Immune System—Sprinting Towards Immune Protection for Cell Replacement Therapy" [2] Company Overview - Sana Biotechnology, Inc. is dedicated to creating engineered cells as medicines, aiming to repair and control genes, and replace missing or damaged cells [3] - The company operates in multiple locations including Seattle, WA, Cambridge, MA, South San Francisco, CA, and Bothell, WA [3]